← Evidence library

BIB_173

Eggermont AMM et al. Adjuvant Pembrolizumab vs Placebo in Resected Stage III Melanoma (KEYNOTE-054). NEJM 2018;378(19):1789–1801. PMID 29658430. Stage III adjuvant pembrolizumab; RFS HR 0.57. Foundational adjuvant ICI. [Tasks: 18, 17] Tier: 1 Grade: A Retrieved: 2026-05-07

Evidence grade

A

Tier

1

Cited by tasks

18, 17

Identifiers

PMID:29658430

↗ Follow the original source for full context

Full extracted findings & patient-implication analysis: bibliography/BIB_173/findings.md (research corpus). This page is a short context summary — not individualised medical advice.